Hematologic toxicities of small molecule tyrosine kinase inhibitors

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Small molecule tyrosine kinase inhibitors (TKIs) are vital targeted anti-cancer therapies.
• While generally safe and effective, TKIs present a risk of specific adverse events.

Purpose of the Study:

• To summarize the spectrum of hematologic toxicities associated with commonly used small molecule TKIs.
• To provide practical management strategies for these TKI-induced hematologic toxicities.

Main Methods:

• Literature review of hematologic toxicities linked to small molecule TKIs.
• Synthesis of clinical data on adverse event profiles.
• Compilation of evidence-based management guidelines.

Main Results:

• Hematologic toxicities, particularly cytopenias (anemia, neutropenia, thrombocytopenia), are common adverse effects of TKIs.
• Less frequent but serious toxicities include thrombotic microangiopathy and splenic infarction.
• Early identification of these toxicities is key to successful treatment.

Conclusions:

• Close patient monitoring is essential for early detection of TKI-related hematologic toxicities.
• Effective management strategies can improve therapeutic efficacy and patient outcomes.
• Understanding and addressing these side effects is critical for optimal TKI use.